LONG TERM Study — LDL-C Efficacy 150 mg (in ASCVD & HeFH)

On top of maximally tolerated statins,

PRALUENT® (alirocumab) 150 mg: The power of 58% LDL-C reduction in the LONG TERM Study1

Rapid and sustained low-density lipoprotein (LDL-C) reduction over the long term (52 weeks) in patients with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH)1

  • Recommended starting dose: 75 mg once every 2 weeks administered subcutaneously or alternatively 300 mg once every 4 weeks (monthly) for patients who prefer less frequent dosing. The majority of patients achieve sufficient LDL-C reduction with the 75-mg dosage1*
  • The lipid-lowering effect of PRALUENT: A rapid reduction in LDL-C was observed in the first 4 weeks2
  • ASCVD population: Overall, 69% were non-FH patients with clinical ASCVD (and 18% had HeFH)1
View examples of patients with ASCVD
or HeFH

NEXT: PRALUENT LDL-C Efficacy 75 mg/150 mg (in ASCVD)

  1. PRALUENT® (alirocumab) Prescribing Information. Sanofi/Regeneron Pharmaceuticals, 2017.
  2. Data on file, Sanofi/Regeneron.

Download Resources